Clinical Features
Migraine is an episodic brain disorder that affects about 12% to 15% of the population
29 and can be highly disabling.
9 It has been estimated to be the most costly neurologic disorder in the European Community at more than &U20AC;27 billion per year,
30 and its cost to the US economy was a staggering $19.6 billion per year more than a decade ago.
31 Migraine presents with headache generally accompanied by features, such as sensitivity to light, sound, or movement, and often with nausea, or less often vomiting (see
Table 61.3). None of the features is compulsory and indeed, given that the migraine aura, visual disturbances with flashing lights or zigzag lines moving across the fields or other neurologic symptoms, is reported in only about 25% of patients, a high index of suspicion is required to diagnose migraine. In a controlled study of patients presenting to primary care physicians with a main complaint of headache over the previous 3 months, migraine was the diagnosis on more than 90% of occasions
10; thus, a high index of suspicion is important. A headache diary can often be helpful in making the diagnosis, although in reality, usually the diary helps more in assessing disability or recording how often patients use acute attack treatments. Phenotyping remains an essentially clinical art mixing experience and an understanding of the problems likely to present:
Good headache histories are taken not given. In differentiating the two main primary headache syndromes seen in clinical practice,
migraine at its simplest is headache with associated features, and tension-type headache is headache that is featureless; furthermore,
most disabling headache presentations in primary care are probably migrainous in biology. By features, here is meant throbbing pain; sensitivity to sensory stimuli: visual, auditory, olfactory; or to head movement itself.
Frequent Migraine
If headache with associated features describes migraine attacks, then
headachy describes the migraine sufferer over his or her lifetime. It is important to realize that the word migraine can both describe the attacks using standard criteria (see
Table 61.3) and describe the disorder itself, which is more than just the attacks. The migraine sufferer inherits a tendency to have headache that is amplified at various times by their interaction with their environment, the much-discussed triggers. The brain of the migraineur seems more sensitive to sensory stimuli and to change, and this tendency is notably amplified in females during their menstrual cycle. Migraine sufferers may have headache when they oversleep, when tired, when they skip meals, when they overexert, when stressed, or when they relax from a stressor. They are less tolerant to change, and part of successful management is to advise them to maintain regularity in their lives in the knowledge of this fluctuating biology. It is this biology that marks migraine and in clinical practice must override the phenotype of individual headaches. Chronic migraine is the largest part of the group of headaches known collectively as
chronic daily headache, a term best not often employed because almost invariably, a more specific diagnosis can be made.
Chronic migraine currently requires some 15 days a month of headache of which 8 are clearly migrainous and with a predating history of migraine.
6 After making a diagnosis, the second step in the clinical process is to be sure that the disease burden has been captured, how much headache does the patient have and more important, what can the patient not do; what is his or her degree of disability? One can ask the patient directly to get a flavor for this, keep a diary or get a quick but accurate estimate using the Migraine Disability Assessment Scale (MIDAS), which is well validated and very easy to use in practice (
Fig. 61.4).
Nonpharmacologic Management of Migraine
This approach aims to help the migrainous patient identify things making the problem worse and encouraging them to modify these. Patients need to know that the brain sensitivity to triggers in migraine varies. Patient associations are often very helpful in supporting migraineurs to identify triggers. The knowledge that there is variability will remove considerable frustration on the patient’s part and will ring true to most as they have had the experience. The crucial lifestyle advice is to explain to the patient that migraine is a state of brain sensitivity to change. This implies that the migraine sufferer needs to regulate their lives: healthy diet, regular exercise, regular sleep patterns, avoiding excess caffeine and alcohol, and, as far as practical, modifying or minimizing changes in stress. The balanced life with less highs and lows will benefit most migraine sufferers.
Preventive Treatments of Migraine
The patient needs to understand they have an inherited, noncurable but manageable problem. To start a preventive, they need to have sufficient disability to wish to take a medicine to reduce the effects of the disease on their life. The basis of considering preventive treatment from a medical viewpoint is a combination of acute attack frequency and attack tractability that is conferring an unacceptable degree of disability. Patients with attacks unresponsive to abortive medications are easily considered for prevention, whereas patients with simply treated
attacks may be less obvious candidates. Another important consideration is disease progress. If a patient diary shows a clear trend of an increasing frequency of attacks, it is better to initiate a preventive than wait for the problem to worsen.
A simple rule for frequency might be that for one to two headaches a month, there is usually no need to start a preventive; for three to four, it may be needed but not necessarily; and for five or more per month, prevention should definitely be considered. Options available for treatment are covered in detail in
Table 61.4 and vary by country. One problem with preventives is that they have fallen into use for migraine from other indications and often bring unwanted or intolerable side effects. It is not clear how preventives work, although it seems likely that they modify the brain sensitivity that underlies migraine. Another key clinical point is that generally, each drug should be started at a low dose and gradually increased to a reasonable maximum if there is going to be a clinical effect.
New advances: The development of migraine-specific preventives is on us as monoclonal antibodies to the calcitonin gene-related peptide (CGRP) pathway are nearing the clinic; effective and well tolerated, a new era is beginning.
32 There are four monoclonal antibodies effective in both episodic and chronic migraine: three to CGRP, eptinezumab,
33,34 fremanezumab,
35,36 and galcanezumab,
37,38 and one to the receptor, erenumab.
39,40 Neuromodulation or neurostimulation approaches are promising as patients and physicians seek nonpharmaceutical approaches to treatment
41; the best established of these being single-pulse transcranial magnetic stimulation (sTMS).
42,43
Acute Attack Therapies of Migraine
Acute attack treatments for migraine can be usefully divided into disease-nonspecific treatments, analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs), disease-specific treatments, ergot-related compounds, and triptans (
Table 61.5). It is important to be aware that most acute attack medications seem to have
a propensity to aggravate headache frequency and can induce a state of refractory daily, near-daily, or medication overuse headache. As evidence is gathered, this seems to occur in patients with migraine, either a previous clear history or a family or personal history of
headacheyness.
44 Codeine-containing analgesics are particularly troublesome when available in over-the-counter (OTC) preparations. One should advise patients with migraine to avoid taking acute attack medicines on more than 2 days a week. A proportion of patients who stop taking regular analgesics will have substantial improvement in their headache with a reduction in frequency; however, for some, it will not make any difference. It is crucial to emphasize to the patient that standard preventive medications often simply do not work in the presence of regular analgesic use.
Treatment strategies: Given the array of options to control an acute attack of migraine, how does one start? The simplest approach to treatment has been described as
stepped care. In this model, all patients are treated, assuming no contraindications, with the simplest treatment, such as aspirin 900 mg or paracetamol (acetaminophen) 1,000 mg with an antiemetic. Aspirin is an effective strategy, has been proven so in double-blind controlled clinical trials, and is best used in its most soluble formulations. The alternative would be a strategy known as
stratified care, by which the physician determines, or stratifies, treatment at the start based on likelihood of response to levels of care. An intermediate option may be described as stratified care by attack. The latter is what many headache authorities suggest and what patients often do when they have the options.
45 Patients use simpler options for their less severe attacks relying on more potent options when their attacks or circumstances demand them.
Nonspecific acute migraine attack treatments: Simple drugs, such as aspirin and paracetamol (acetaminophen), are cheap and can be effective. Dosages should be adequate and the addition of domperidone (10 mg orally) or ondansetron (4 mg) or aprepitant (80 mg) can be very helpful. NSAIDs can very useful when tolerated. Their success is often limited by inappropriate dosing, and adequate doses of naproxen (500 to 1,000 mg orally or rectally, with an antiemetic), ibuprofen (400 to 800 mg orally),
46 or tolfenamic acid (200 mg orally)
47 can be extremely effective.
Specific acute migraine attack treatments: When simple analgesic measures fail or more aggressive treatment is required, the specific antimigraine treatments are required (
Table 61.6). Although ergotamine remains a useful treatment, it can no longer be considered the treatment of choice in acute migraine.
48 There are particular situations in which ergotamine is very helpful, but its use must be carefully controlled as ergotamine overuse produces dreadful headache in addition to a host of vascular problems. The triptans, serotonin 5-HT
1B/1D receptor agonists, have revolutionized the life of many patients with migraine and are clearly the most powerful option available to stop a migraine attack. They can be rationally applied by considering their pharmacologic, physicochemical, and pharmacokinetic features
49 as well as the formulations that are available.
45 Recent data suggests that combining a triptan with an NSAID can improve efficacy and reduce headache recurrence.
50
New advances: There are exciting new developments in acute therapy of migraine that are on the horizon. Neuromodulation approaches with supraorbital stimulation,
51 noninvasive vagus nerve stimulation (nVNS),
52 and transcranial magnetic stimulation
53 each have controlled trials and an interesting physiologic basis.
54,55 They offer patients a nonpharmaceutical option. What has been sought almost since the launch of the triptans is effective acute antimigraine treatments without vasoconstrictor effects.
8 The development of lasmiditan, a serotonin 5-HT
1F receptor agonist, or
ditan, that is without vasoconstrictor effects,
56 yet works in clinic in phase II
57 and now in two phase III studies,
58 is an important development. Similarly, the development of small molecule CGRP receptor antagonists, or
gepants, notably now rimegepant
59 and ubrogepant,
60 which are both effective in treating acute migraine, and come from a clearly safe class of treatments,
61 again offers the real promise of an important advance for patients.